Cargando…
Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938747/ https://www.ncbi.nlm.nih.gov/pubmed/31722117 http://dx.doi.org/10.1111/1759-7714.13233 |
| _version_ | 1783484088067293184 |
|---|---|
| author | Hu, Weixian |
| author_facet | Hu, Weixian |
| author_sort | Hu, Weixian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6938747 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley & Sons Australia, Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69387472020-01-06 Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy Hu, Weixian Thorac Cancer Editorials John Wiley & Sons Australia, Ltd 2019-11-12 2020-01 /pmc/articles/PMC6938747/ /pubmed/31722117 http://dx.doi.org/10.1111/1759-7714.13233 Text en © 2019 The Author. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorials Hu, Weixian Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy |
| title | Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy |
| title_full | Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy |
| title_fullStr | Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy |
| title_full_unstemmed | Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy |
| title_short | Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy |
| title_sort | multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and pd‐l1 immunohistochemistry for predicting response to anti‐pd‐1/pd‐l1 immunotherapy |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938747/ https://www.ncbi.nlm.nih.gov/pubmed/31722117 http://dx.doi.org/10.1111/1759-7714.13233 |
| work_keys_str_mv | AT huweixian multipleximmunohistochemistryimmunofluorescenceissuperiortotumormutationalburdenandpdl1immunohistochemistryforpredictingresponsetoantipd1pdl1immunotherapy |